[Asia Economy Reporter Minji Lee] KPMTec announced on the 25th that it has applied to the Ministry of Food and Drug Safety for approval of an Investigational New Drug (IND) application for a bridging clinical trial of the novel coronavirus disease (COVID-19) treatment Lenzilumab.
The company stated, "We will evaluate the safety, tolerability, and pharmacokinetic characteristics of intravenous administration of Lenzilumab in domestic adults," adding, "Subsequently, we will comparatively assess the safety, tolerability, and pharmacokinetic characteristics with those of Western populations."
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
